A new report from the Medicines and Healthcare products Regulatory Agency (MHRA) has set out the public's view on AI in healthcare.

Following an extensive engagement and evidence gathering programme, two reports have now been published. These will inform future rules on how AI can be used safely in healthcare.

The research was carried out to support the independent National Commission into the Regulation of AI in Healthcare.

With insight from patients, the public, healthcare professionals, industry and system partners, the the public, healthcare professionals, industry and system partners. The Research and Engagement report sets out one of the most comprehensive evidence bases to date on how AI is currently perceived, used and governed across the UK health system.

Findings from a recent Call for Evidence have also been published.

Both reports show a recognition of the potential benefits of AI in healthcare, provided that rules appropriately set standards for safety and efficacy. There is also a broad consensus that existing regulatory approaches need to be adapted to meet the rapid pace of change and development of AI technology.  

Chair of the National Commission into the Regulation of AI in Healthcare, Professor Alastair Denniston, said: “This programme of research and evidence gathering from people across the UK has been an absolutely critical part of the National Commission, and will directly influence the final recommendations we make. I would like to personally thank everyone for their contributions, taking the time to contribute their experience, insights and views.

“The increasing AI in healthcare will affect all of us. These views consistently highlight the potential to bring many benefits, enhancing quality, speed, convenience and increasing safety, but also highlights that this is a change that the regulators and wider health system need to actively engage with, including ensuring that our regulations and governance systems match the risks and benefits of these new technologies.” 

Lawrence Tallon, Chief Executive of the MHRA, said: “Our role is to ensure patients can benefit from innovation while remaining appropriately protected. The evidence published today provides an essential foundation for getting that balance right, supporting a regulatory approach that is proportionate, adaptive and grounded in real-world use.

“We will continue to work closely across the system to ensure the UK remains a leader in the safe and effective use of AI in healthcare.”